ABCAM PLC Total Voting Rights (5660A)
June 02 2021 - 4:54AM
UK Regulatory
TIDMABC
RNS Number : 5660A
ABCAM PLC
02 June 2021
For immediate release 02 June 2021
ABCAM PLC
("Abcam" or "Company")
Total Voting Rights - Voting Rights and Capital
In conformity with the Disclosure Rules and Transparency Rules,
provision 5.6.1, the Company notifies the market of the
following:
The Company's issued share capital consists of 226,747,719
Ordinary Shares of 0.2p each with voting rights. The Company does
not hold any shares in Treasury.
The above figure of 226,747,719 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in the Company under the FCA's Disclosure and
Transparency Rules.
Date of Notification: 02 June 2021
For further information please contact:
+ 44 (0) 1223 696
Abcam 000
Marc Perkins, Company Secretary
Numis - Nominated Adviser & Joint Corporate + 44 (0) 20 7260
Broker 1000
Garry Levin / Huw Jeremy
J.P.Morgan Cazenove - Joint Corporate Broker +44 (0) 20 7742
James Mitford / Hemant Kapoor 4000
Morgan Stanley - Joint Corporate Broker +44 (0) 20 425
Tom Perry / Luka Kezic 8000
FTI Consulting +44 (0) 20 3727
Ben Atwell / Natalie Garland-Collins 1000
Notes to Editors
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health. Two-thirds of the world's 750,000 life science
researchers use Abcam's affinity binders, reagents, biomarkers and
assays and the Company's products are mentioned in over 20,000 of
the 56,000 peer-reviewed papers published each year in the life
sciences.
By actively listening to and collaborating with researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Abcam's thirteen locations are in the world's leading life
science research hubs, enabling local services and multi-language
support. Founded in 1998 and headquartered in Cambridge, UK, the
Company sells to more than 100 countries. Abcam was admitted to AIM
in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRUPUGAQUPGURP
(END) Dow Jones Newswires
June 02, 2021 04:54 ET (08:54 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024